Latest Distributions News

Waypoint REIT reported steady distributable earnings of $55.6 million for the first half of 2025, supported by robust property valuations and disciplined capital management. Despite flat earnings, statutory net profit surged nearly 47%, reflecting significant valuation gains.

Nutritional Growth Solutions reported a 30% drop in revenue to US$867k for H1 FY25 but narrowed its loss to US$1.2 million, driven by cost discipline and new retail partnerships including Walmart and CVS.

BlackRock is reshaping its iShares Future Tech Innovators ETF by narrowing its focus to the 30 largest Nasdaq 100 companies and cutting management fees nearly in half, effective October 15, 2025.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Volt Group Limited reports a 38% surge in EcoQuip revenue alongside steady progress in zero-emission technologies, positioning itself strongly in the clean energy transition.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.